Sirukumab

Drug Profile

Sirukumab

Alternative Names: CNTO-136; Shirukumabu

Latest Information Update: 10 Jan 2017

Price : $50

At a glance

  • Originator Centocor
  • Developer Centocor; GlaxoSmithKline; Janssen Biotech
  • Class Antirheumatics; Monoclonal antibodies
  • Mechanism of Action Interleukin 6 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Rheumatoid arthritis
  • Phase III Giant cell arteritis
  • Phase II Asthma; Lupus nephritis; Major depressive disorder
  • Preclinical Atherosclerosis

Most Recent Events

  • 01 Dec 2016 Janssen Research & Development and GlaxoSmithKline completes the phase III SIRROUND-D trial for Rheumatoid arthritis in USA, Argentina, Brazil, Bulgaria, Canada, Chile, Colombia, Croatia, India, Japan, Lithuania, Malaysia, Mexico, Poland, Romania, Russia, Serbia, South Africa, South Korea, Taiwan and Ukraine (NCT01604343)
  • 16 Nov 2016 Efficacy and adverse events data from the phase III SIRROUND-H and SIRROUND-T trials in Rheumatoid arthritis released by Janssen
  • 20 Oct 2016 Preregistration for Rheumatoid arthritis in Japan (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top